Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis

Xueyong Liu _, Zhan Zhang, Chunbo Deng, Yihao Tian and Xun Ma

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:62769-62779. https://doi.org/10.18632/oncotarget.19370

Metrics: PDF 1949 views  |   HTML 3768 views  |   ?  


Xueyong Liu1, Zhan Zhang2, Chunbo Deng3, Yihao Tian1 and Xun Ma1

1Department of Spine and Joint Surgery, Shengjing Hospital of China Medical University, Shenyang, China

2Department of Spine Surgery, Shengjing Hospital of China Medical University, Shenyang, China

3Department of Orthopedics, Fengtian Hospital of Shenyang Medical College, Shenyang, China

Correspondence to:

Xueyong Liu, email: [email protected]

Keywords: ERCC, meta-analysis, polymorphism, osteosarcoma, prognosis

Received: October 10, 2016     Accepted: July 11, 2017     Published: July 19, 2017


To investigate correlations between excision repair cross-complementation group 1 (ERCC1) and 2 (ERCC2) polymorphisms and osteosarcoma prognosis, we conducted a meta-analysis of studies published through October 2016. Studies were identified in the PubMed, ScienceDirect, Springer, and Web of Science databases using preferred reporting items for systematic reviews and meta-analyses (PRISMA). Odds ratios (ORs) or hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS), tumor response (TR), and event-free survival (EFS) were estimated. Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated. Each of these studies scored > 6 on the Newcastle-Ottawa Scale (NOS). We found that only one SNP, ERCC1 rs11615, correlated with improved OS and TR. The HR of T vs. C for OS was 1.455 (T/C, 95% CI = 1.151–1.839, P = 0.002, I2 = 37.80%). The OR of T vs. C for good TR was 0.554 (T/C, 95% CI = 0.437–0.702, P < 0.001, I2 = 0%). Few significant outcome was observed in subgroup analyses stratified based on study characteristics with adjustments for potential confounders. Our results suggest that ERCC1 rs11615 CC is associated with a better clinical outcome. This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19370